MDMA ("ecstasy") has been widely reported as a drug of abuse and as a neurotoxin. This report describes the mechanism ofMDMA action at serotonin transporters from plasma membranes and secretory vesicles. MDMA stimulates serotonin efflux from both types of membrane vesicle. In plasma membrane vesicles isolated from human platelets, MDMA inhibits serotonin transport and [3H]imipramine binding by direct interaction with the Na+-dependent serotonin transporter. MDMA stimulates radiolabel efflux from plasma membrane vesicles preloaded with PHlserotonin in a stereospecific, Na+-dependent, and imipramine-sensitive manner characteristic of transporter-mediated exchange. In membrane vesicles isolated from bovine adrenal chromaffmi granules, which contain the vesicular biogenic amine transporter, MDMA inhibits ATP-dependent [3H]serotonin accumulation and stimulates efflux of previously accumulated [3H]serotonin.
Stimulation of vesicular [3Hlserotonin efflux is due to dissipation of the transmembrane pH difference generated by ATP hydrolysis and to direct interaction with the vesicular amine transporter.
Serotonin transport has been implicated in the mechanism of a number of amphetamine derivatives including p-chloroamphetamine, fenfluramine, 3,4-methylenedioxyamphetamine, and MDMA. These compounds cause an acute release of serotonin in vivo (1, 2) and in vitro (3) (4) (5) and also lead to a long-term depletion of serotonin (6, 7) that correlates with morphological damage to serotonergic nerve endings (7) (8) (9) (10) . The serotonin transporter has been implicated in these phenomena since inhibitors of serotonin transport block the effect of amphetamine derivatives on acute serotonin release and destruction of serotonergic terminals (5, 11, 12) . These results suggest that the serotonin transporter either mediates the entry of neurotoxic amphetamines into serotonergic terminals or participates in sequelae leading to serotonin release and depletion (13) or both.
The observation that Ca2+ is not required for amphetamine-induced serotonin release (4) suggests that exocytosis is not involved. Thus, it is likely that amphetamines may induce release by reversal of the transport systems that normally catalyze accumulation of serotonin to high levels within the neuron and the synaptic vesicle. We, therefore, examined two membrane vesicle model systems for serotonin transport to determine if MDMA directly affects these transport systems. Serotonergic neurons, like other cells that secrete serotonin, contain two serotonin transport systems that function in series (14) . One of these systems transports serotonin into the cell, and the other sequesters intracellular serotonin within secretory vesicles.
Purified platelet plasma membrane vesicles contain the Na+-dependent imipramine-sensitive serotonin transporter responsible for serotonin reuptake into presynaptic nerve endings (15) . When appropriate transmembrane ion gradients are imposed, these vesicles accumulate [3H]serotonin to concentrations several hundredfold higher than in the external medium. Transport requires external Na' and Cl-and is stimulated by internal K+ (16) (17) (18) . Results from a variety of experiments suggest that serotonin is transported across the membrane with Na' and Cl-in one step of the reaction and that K+ is transported in the opposite direction in a second step (19) .
Membrane vesicles isolated from bovine adrenal chromaffin granules accumulate biogenic amines, including serotonin, by an HW-coupled transport system driven by ATP hydrolysis (20) . Apparently, the same system is responsible for amine uptake into secretory vesicles from platelets, mast cells, and nerve endings (21) (22) (23) . The system consists of two components: (i) an ATP-driven H' pump, the vacuolar ATPase, which acidifies the vesicle interior and also generates a transmembrane electrical potential (Aq+, interior positive) (24) , and (ii) the reserpine-sensitive vesicular amine transporter, which couples efflux of one or more H' ions to the uptake of each molecule of biogenic amine (25) .
Previous work (3) (4) (5) in vitro using MDMA has been performed with synaptosomes or brain slices. Those studies did not distinguish between effects on the plasma membrane and vesicular transporters. In the present work, we have examined the interaction of MDMA with each of these transporters separately. The results suggest that MDMA is a substrate for both transport systems and imply that MDMA causes serotonin release by stimulating serotonin-MDMA exchange.
EXPERIMENTAL PROCEDURES Membrane Vesides. Outdated human platelet concentrates were purchased from the Connecticut Red Cross. Platelets from 50 to 100 individuals were pooled for each membrane preparation. Platelet plasma membrane vesicles were isolated by the method of Barber and Jamieson (26) with the modifications described (27) . Chromaffin granule membrane vesicles were prepared as described by Schuldiner et al. (28) by repeated osmotic lysis of bovine adrenal medullary chromaffin granules isolated by differential sedimentation.
Transport Assays. Transport of serotonin into plasma membrane vesicles was measured at 250C using the filtration assay (15) . Unless otherwise indicated, vesicles were equilibrated with 10 mM lithium phosphate (pH 6.7) containing 133 mM K2SO4 and 1 mM MgSO4 and diluted into external medium containing 0.2 M NaCl, 10 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
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Biochemistry: Rudnick and Wall containing 10 mM Hepes (adjusted to pH 8.5 with KOH), 5 mM KCI, 2.5 mM MgSO4, 5 mM disodium ATP, and 0.1 ,uM [3H] serotonin, which is below the Km for transport. Reactions (200 1.l per assay) were stopped by dilution, filtration, and washing, and radioactivity in filtered vesicles was measured as described (28) . The standard error of replicate assay values was typically <5% of the mean.
Serotonin Efflux and Exchange. Platelet plasma membrane vesicles equilibrated with 10 mM lithium phosphate (pH 6.7) containing 60 mM NaCl, 93 mM K2SO4, and 1 mM MgSO4 were diluted 1:30 into 0.2 M NaCl containing 10 mM lithium phosphate (pH 6.7) and 0.1 ,uM [3H]serotonin at 25TC. After serotonin accumulation had reached a maximum (5-10 min), efflux was initiated by a 1:40 dilution of the suspension with the indicated medium. After a 30-sec incubation, the vesicles were collected by filtration through Gelman GN-6 nitrocellulose filters. The filter and reaction tube were rapidly rinsed with 2 ml of ice-cold 0.2 M NaCl, and radioactivity in the filter was measured in 3 ml of Optifluor (Packard). Efflux from chromaffin granule membrane vesicles was measured in the same way, except that preloading was carried out for 40 min in 0.3 M sucrose containing 10 mM Hepes adjusted to pH 8.5 (with KOH), 5 mM KCl, 2.5 mM MgSO4, 5 mM disodium ATP, and 0.1 ,uM [3H]serotonin and efflux was measured 11 min after dilution into the same medium without ATP, MgSO4, or [3H]serotonin. The standard error of replicate assay values was typically <10% of the mean.
Imipramine Binding. Imipramine binding was measured at 25°C using the filtration assay described (29) . Briefly, to initiate binding, membrane vesicles were suspended at a protein concentration of 0.3 mg/ml in an assay buffer of 200 mM NaCl containing 10 mM LiH2PO4 (pH 6.7) and 1 mM MgSO4. The assay buffer also contained 0.9 nM [3H]imipramine (48 cpm/fmol), a concentration below the Kd under these conditions. After a 15-min incubation, the reactions (300,ul per assay) were terminated by dilution with 4 ml of ice-cold isoosmotic NaCl and filtered through Whatman GF/B filters pretreated with 0.5% polyethyleneimine. The tube and filter were washed three times with 4 ml of ice-cold NaCl solution. Filters were placed in 3 ml of Optifluor and radioactivity was measured after 5 hr. Binding in the absence of Na+ or in the presence of 100 ,tM serotonin was taken as a control for nonspecific binding. The standard error of replicate assay values was typically <5% of the mean.
Transmembrane pH Difference (ApH) Measurements.
Chromaffin granule membrane vesicles (80 ,ug of protein) were incubated at room temperature in a cuvette containing 2 ml of 10 mM N-(2-hydroxyethyl)piperazine-N'-(3-propanesulfonic acid (Epps) (adjusted to pH 8.5 with KOH), 150 mM KCI, 6 ,uM acridine orange, 0.2 mM EDTA, and 5 mM ATP. The relative fluorescence of the mixture was measured using an excitation wavelength of 490 nm and an emission wavelength of 526 nm on a Perkin-Elmer LS-SB luminescence spectrometer. After the baseline fluorescence stabilized, acidification was initiated by the addition of 6 mM MgSO4, and the relative fluorescence was monitored. (Fig. 1, dashed lines) is similar to that for its inhibition of serotonin influx. Furthermore, the stereospecificity observed for inhibition of transport and binding is maintained for MDMA-induced efflux, with the (+)-isomer being more potent (Fig. 1) .
The results in more potent than NH4Cl at stimulating efflux, with a halfmaximal activity at <200 uM (Fig. 3, triangles) , compared to 1 mM for NH4Cl.
In separate experiments, we tested the stereospecificity of MDMA-induced serotonin efflux. At 300 ILM, (+)-MDMA caused 64 ± 2% efflux of serotonin and (-)-MDMA caused 48 ± 4% efflux within the same il-min period.
Stimulation of serotonin efflux, and inhibition ofits uptake, could reflect the ability of MDMA to be transported by the vesicular amine transporter. As a weakly basic amine, however, MDMA can also dissipate, by passive nonionic diffusion, the ApH that drives transport. To evaluate these possibilities, we measured the ability of MDMA to dissipate ApH as measured by acridine orange fluorescence quenching. The results in Fig. 3 (circles) demonstrate that MDMA dissipates ApH with half-maximal effect at -1 mM and that each isomer is equally active. Although the assays are different, MDMA appears to be more potent at stimulating efflux than at dissipating ApH (Fig. 3) . This result and the stereospecificity of MDMA-induced effiux suggest that, although MDMA dissipates ApH, it may also exchange with serotonin through the amine transporter.
DISCUSSION
The results presented here using two membrane vesicle model systems demonstrate that MDMA directly and indirectly stimulates serotonin efflux through the plasma membrane and vesicular membrane transport systems responsible for serotonin reuptake and storage in nerve terminals. In plasma membrane vesicles, MDMA-induced efflux is evidently mediated by the serotonin transporter, since the process requires Na+ on both sides of the membrane and is blocked by imipramine. Direct interaction of MDMA with the transporter is illustrated also by its ability to displace [3H] (31, 33, 34) in which a transported substrate or inhibitor has a lower Km or K; relative to its true dissociation constant measured in equilibrium binding studies.
The stereospecificity of the actions of MDMA at the serotonin transporter mirrors the higher potency of (+)-MDMA in behavioral studies (35) . This contrasts with the higher potency of the R (-)-isomer for hallucinogenic amphetamines (36) . Our results are, therefore, consistent with the possibility that behavioral effects of MDMA are mediated through its actions at the serotonin transporter.
Efflux from vesicular membranes is more complex, since MDMA dissipates the ApH (interior acid) in addition to its direct effect on the vesicular amine transporter. The ApH is generated by the vacuolar ATPase, which pumps H+ ions into the vesicle interior (24 (1992) MDMA to readily diffuse across membranes and its ability to serve as a transport substrate suggest a mechanism for MDMA-induced serotonin release by nerve terminals. Extracellular MDMA is expected to enter cells either passively or by way ofthe serotonin transporter and then enter synaptic vesicles in a process that consumes intravesicular H' ions. MDMA may cause serotonin efflux from the vesicle to the cytoplasm by increasing internal pH or by preferentially inhibiting influx relative to efflux, as was shown for tyramine (38) . Before cytoplasmic serotonin can be oxidized by monoamine oxidase, exchange with extracellular MDMA catalyzed by the plasma membrane serotonin transporter leads to serotonin efflux from the cell. This process would explain the relative lack of5-hydroxyindoleacetic acid in MDMA-treated animals compared to those treated with reserpine (39) . Reserpine depletes vesicular monoamines but does not influence the plasma membrane transporter (14) .
Other amphetamine derivatives that cause serotonin release, such as 3,4-methylenedioxyamphetamine, p-chloroamphetamine, and fenfluramine, may also be substrates for serotonin transport systems. The neurotoxic potential of these compounds may be related to their ability to exchange with serotonin or to dissipate transmembrane ion gradients and thereby tax energy metabolism in the nerve terminal. Moreover, drugs that release catecholamines, such as amphetamine and methamphetamine, may also act by depleting vesicular stores and exchanging through the plasma membrane catecholamine transport systems. Studies with synaptosomal preparations provide some support for this hypothesis (40, 41) . Indeed, the specificity of plasma membrane biogenic amine transporters may play an important role in determining the sensitivity of a given aminergic neuron to amphetamines.
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